Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC).

被引：27

作者：

Kim, Dong-Wan

Gadgeel, Shirish M.

Gettinger, Scott N.

Riely, Gregory J.

Oxnard, Geoffrey R.

Mekhail, Tarek

Schmid, Peter

Dowlati, Afshin

Heist, Rebecca Suk

Wozniak, Antoinette J.

Hernandez, Genevive

Sarkar, Indrani

Mitry, Emmanuel

Foster, Paul

O'Hear, Carol

Spahn, Jessica

Ou, Sai-Hong Ignatius

机构：

[1] Seoul Natl Univ Hosp, Seoul, South Korea

[2] Univ Michigan, Ann Arbor, MI USA

[3] Yale New Haven Med Ctr, Yale Canc Ctr, New Haven, CT USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Florida Hosp Canc Inst, Orlando, FL USA

[7] Barts Canc Inst, London, England

[8] UH Cleveland Med Ctr, Cleveland, OH USA

[9] Massachusetts Gen Hosp, Boston, MA USA

[10] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[11] Genentech Inc, San Francisco, CA USA

[12] F Hoffmann Roche Ltd, Basel, Switzerland

[13] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9009

引用

页数：1